Limited data exist on outcomes in mRCC patients with major venous involvement (MVI). Assessment of impact of a given variable on prognosis in cancer patients is challenging given competing causes of ...
For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...
Simple blood markers may predict nivolumab outcomes in metastatic renal cell carcinoma. Learn how eosinophils could help ...
Phase I Study Combining Treatment With Temsirolimus and Sunitinib Malate in Patients With Advanced Renal Cell Carcinoma This phase I study evaluated temsirolimus in combination with sunitinib in ...
Symptoms of stage 3 RCC vary; some patients experience blood in the urine, flank pain, fatigue, weight loss, or a palpable abdominal mass, whereas others are diagnosed incidentally during imaging for ...
Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
Renal cell carcinoma is the most common form of kidney cancer. It can take time to fully process a diagnosis and what, ...
ITM-94, a gallium-68-radiolabeled PET imaging agent, targets carbonic anhydrase IX, crucial in tumor growth and metastasis. The FDA's fast track designation aims to expedite ITM-94's development for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback